{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:15:52Z","timestamp":1788243352350,"version":"build-2803163510"},"reference-count":65,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Technovalia"},{"DOI":"10.13039\/100032162","name":"BioNet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100032162","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Despite high childhood coverage and booster doses of pertussis vaccination across the life course, pertussis (whooping cough) outbreaks continue to occur, including in Australia and New Zealand. In January 2026, the European Medicines Agency (EMA) granted marketing authorisation to a new pertussis-only booster vaccine (VacPertagenTM): the first time in two decades that a new acellular pertussis vaccine has been approved in the European Union. Anticipating future licensure of the vaccine in Australia and New Zealand, an expert panel was convened to discuss the clinical and programmatic advantages that this new vaccine may offer in the context of current pertussis epidemiology and vaccination strategies inSuch advantages may also be applicable to other high-income countries experiencing ongoing pertussis outbreaks.<\/jats:p>","DOI":"10.3390\/vaccines14090736","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:11:15Z","timestamp":1787731875000},"page":"736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Expert Perspective on a New Recombinant Pertussis-Only Vaccine and Its Potential Clinical and Programmatic Advantages in Australia, New Zealand, and Beyond"],"prefix":"10.3390","volume":"14","author":[{"given":"Peter","family":"McIntyre","sequence":"first","affiliation":[{"name":"Department of Women\u2019s and Children\u2019s Health, School of Medicine, University of Otago, 362 Leith Street, North Dunedin, Dunedin 9016, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-7261","authenticated-orcid":false,"given":"Anita H. J.","family":"van den Biggelaar","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, 15 Hospital Avenue, Nedlands, WA 6009, Australia"},{"name":"BioNet, 19 Soi Udomsuk 37, Sukhumvit 103 Road, Bangjak, Prakanong, Bangkok 10260, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9151-4781","authenticated-orcid":false,"given":"Frank","family":"Beard","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine and Health, The University of Sydney, 1 Western Avenue, Camperdown, NSW 2050, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-4150","authenticated-orcid":false,"given":"Mary","family":"Nowlan","sequence":"additional","affiliation":[{"name":"Immunisation Advisory Centre, Department of General Practice and Health Care, The University of Auckland, Private Bag 92019, Victoria St West, Auckland 1142, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette K.","family":"Regan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, 650 Charles E Young Dr S, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Pearce","sequence":"additional","affiliation":[{"name":"Medical HQ Glynde, 127 Glynburn Road, Adelaide, SA 5070, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-3863","authenticated-orcid":false,"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[{"name":"Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hughes","sequence":"additional","affiliation":[{"name":"Immunisation Foundation of Australia, P.O. Box 186, Bassendean, WA 6935, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7562-7228","authenticated-orcid":false,"given":"Peter","family":"Richmond","sequence":"additional","affiliation":[{"name":"Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, 15 Hospital Avenue, Nedlands, WA 6009, Australia"},{"name":"School of Medicine, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e2545963","DOI":"10.1001\/jamanetworkopen.2025.45963","article-title":"Global Incidence of Pertussis After the COVID-19 Pandemic","volume":"8","author":"Gorringe","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_2","unstructured":"Australian Centre for Disease Control (2026, March 09). National Notifiable Diseases Surveillance System (NNDSS), National Communicable Disease Surveillance Dashboard, Available online: https:\/\/nindss.health.gov.au\/pbi-dashboard\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2023062664","DOI":"10.1542\/peds.2023-062664","article-title":"Maternal Pertussis Vaccination, Infant Immunization, and Risk of Pertussis","volume":"152","author":"Regan","year":"2023","journal-title":"Pediatrics"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.5694\/mja2.51989","article-title":"Influenza and pertussis vaccine coverage in pregnancy in Australia, 2016\u20132021","volume":"218","author":"McRae","year":"2023","journal-title":"Med. J. Aust."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"PU25021","DOI":"10.1071\/PU25021","article-title":"Reporting of pregnancy vaccinations across two data sources, New South Wales, Australia, 2017\u20132022","volume":"36","author":"Sonneveld","year":"2026","journal-title":"Public Health Res. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hull, B., Hendry, A., Macartney, K., and Beard, F. (2026). Annual immunisation coverage report 2024. Commun. Dis. Intell., 50.","DOI":"10.33321\/cdi.2026.50.023"},{"key":"ref_7","unstructured":"The New Zealand Institute for Public Health and Forensic Science (PHF Science) (2026, March 09). Pertussis Report, 20 September\u201317 October 2025. Available online: https:\/\/www.phfscience.nz\/digital-library\/."},{"key":"ref_8","unstructured":"The New Zealand Institute for Public Health and Forensic Science (PHF Science) (2026, March 09). Pertussis Dashboard. Available online: https:\/\/www.phfscience.nz\/digital-library\/pertussis-dashboard\/#pertussisdashboard."},{"key":"ref_9","first-page":"100850","article-title":"Pertussis deaths in New Zealand without community transmission\u2014An infant immunity gap?","volume":"37","author":"McIntyre","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_10","unstructured":"(2026, March 09). The Immunisation Advisory Centre for the National Immunisation Programme at Health New Zealand | Te Whatu Ora. Re-view of Evidence to Inform the New Zealand National Immunisation Programme. Pertussis. Available online: https:\/\/immune.org.nz\/publications\/review-of-evidence-to-inform-the-new-zealand-national-immunisation-programme-2024-pertussis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1056\/NEJMoa1200850","article-title":"Waning Protection after Fifth Dose of Acellular Pertussis Vaccine in Children","volume":"367","author":"Klein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41579-024-01064-8","article-title":"Pertussis vaccines, epidemiology and evolution","volume":"22","author":"Rohani","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_13","unstructured":"European Medicines Agency (EMA) (2026, February 19). VacPertagen. Last Update 21\/01\/2026. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vacpertagen-epar-product-information_en.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Esposito, S., Stefanelli, P., Fry, N.K., Fedele, G., He, Q., Paterson, P., Tan, T., Knuf, M., Rodrigo, C., and Olivier, C.W. (2019). Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01344"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1016\/j.vaccine.2013.08.034","article-title":"Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults\u2014A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience","volume":"31","author":"Dalby","year":"2013","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cmi.2025.03.014","article-title":"Safety of pertussis vaccination in pregnancy and effectiveness in infants: A Danish national cohort study 2019\u20132023","volume":"31","author":"Kildegaard","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1172\/JCI24609","article-title":"Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis","volume":"115","author":"Kirimanjeswara","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Scanlon, K., Skerry, C., and Carbonetti, N. (2019). Association of Pertussis Toxin with Severe Pertussis Disease. Toxins, 11.","DOI":"10.3390\/toxins11070373"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/civ472","article-title":"Risk Factors Associated with Infant Deaths from Pertussis: A Case-Control Study","volume":"61","author":"Winter","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1080\/21505594.2021.1980987","article-title":"Pathogenicity and virulence of Bordetella pertussis and its adaptation to its strictly human host","volume":"12","author":"Belcher","year":"2021","journal-title":"Virulence"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"108972","DOI":"10.1016\/j.toxicon.2025.108972","article-title":"The role of pertussis toxin in clinical manifestations of pertussis","volume":"271","author":"Zhao","year":"2025","journal-title":"Toxicon"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/cid\/cit934","article-title":"The Pertussis Problem","volume":"58","author":"Plotkin","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eaay9258","DOI":"10.1126\/sciadv.aay9258","article-title":"Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons","volume":"6","author":"Nguyen","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/infdis\/jiy022","article-title":"Maternal Vaccination with a Monocomponent Pertussis Toxoid Vaccine Is Sufficient to Protect Infants in a Baboon Model of Whooping Cough","volume":"217","author":"Kapil","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0264-410X(98)00226-6","article-title":"A search for serologic correlates of immunity to Bordetella pertussis cough illnesses","volume":"16","author":"Cherry","year":"1998","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/S0264-410X(03)00407-9","article-title":"Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis","volume":"21","author":"Storsaeter","year":"2003","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1716","DOI":"10.1542\/peds.2012-3836","article-title":"Comparative Effectiveness of Acellular Versus Whole-Cell Pertussis Vaccines in Teenagers","volume":"131","author":"Klein","year":"2013","journal-title":"Pediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e20153326","DOI":"10.1542\/peds.2015-3326","article-title":"Waning Tdap Effectiveness in Adolescents","volume":"137","author":"Klein","year":"2016","journal-title":"Pediatrics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/iai.46.2.415-421.1984","article-title":"Bordetella pertussis infection in mice: Correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system","volume":"46","author":"Sato","year":"1984","journal-title":"Infect. Immun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/iai.58.1.7-16.1990","article-title":"Bordetella pertussis filamentous hemagglutinin: Evaluation as a protective antigen and colonization factor in a mouse respiratory infection model","volume":"58","author":"Kimura","year":"1990","journal-title":"Infect. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e20153973","DOI":"10.1542\/peds.2015-3973","article-title":"Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis","volume":"137","author":"Breakwell","year":"2016","journal-title":"Pediatrics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0264-410X(95)00230-X","article-title":"The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies","volume":"14","author":"Ibsen","year":"1996","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S0264-410X(99)00234-0","article-title":"Genetically derived toxoids for use as vaccines and adjuvants","volume":"17","author":"Rappuoli","year":"1999","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2419457122","DOI":"10.1073\/pnas.2419457122","article-title":"Structural Basis for Antibody Neutralization of Pertussis Toxin","volume":"122","author":"Goldsmith","year":"2025","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(17)30612-6","article-title":"A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: A phase 2\/3, randomised controlled non-inferiority trial","volume":"18","author":"Sricharoenchai","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/cid\/ciy594","article-title":"Boosting Teenagers with Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial","volume":"68","author":"Rohner","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijregi.2023.06.001","article-title":"Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study","volume":"8","author":"Phongsamart","year":"2023","journal-title":"IJID Reg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"128863","DOI":"10.1016\/j.vaccine.2026.128863","article-title":"Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: A randomized, controlled, non-inferiority trial","volume":"88","author":"Ong","year":"2026","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.vaccine.2023.11.042","article-title":"Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines","volume":"42","author":"Chokephaibulkit","year":"2023","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Abu-Raya, B., Del Giudice, G., van den Biggelaar, A.H.J., Tang, Y., Bhat, N., Pham, H.T., and Wijagkanalan, W. (2025). Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1569151"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2449182","DOI":"10.1001\/jamanetworkopen.2024.49182","article-title":"Pertussis Immunity 5 Years After Booster Vaccination with Recombinant Pertussis Vaccines","volume":"7","author":"Pitisuttithum","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100976","DOI":"10.1016\/j.eclinm.2021.100976","article-title":"Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aP(gen) or combined TdaP(gen) vaccines","volume":"37","author":"Pitisuttithum","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/INF.0b013e3181d581f9","article-title":"Post-Marketing Safety Evaluation of a Tetanus Toxoid, Reduced Diphtheria Toxoid and 3-Component Acellular Pertussis Vaccine Administered to a Cohort of Adolescents in a United States Health Maintenance Organization","volume":"29","author":"Klein","year":"2010","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1128\/iai.65.6.2168-2174.1997","article-title":"Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines","volume":"65","author":"Ausiello","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_45","first-page":"45","article-title":"A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults","volume":"14","author":"Lattanzi","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"119352","DOI":"10.1016\/j.socscimed.2026.119352","article-title":"Birth order and infant health: Evidence from maternal immunisation in New Zealand","volume":"401","author":"Schober","year":"2026","journal-title":"Soc. Sci. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/ajo.13146","article-title":"Antenatal vaccine uptake: A cross-sectional study investigating factors influencing women\u2019s choices in pregnancy","volume":"60","author":"Moir","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Maltezou, P.G., Papakonstantinou, M.E., Kourkouni, E., Kousi, D., Hadjichristodoulou, C., Briana, D., and Papaevangelou, V. (2026). Influenza and Pertussis Vaccination During Pregnancy: A Systematic Review of Vaccination Rates and Vaccination Determinants. Vaccines, 14.","DOI":"10.3390\/vaccines14040325"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1473-3099(18)30426-2","article-title":"Genetically modified pertussis toxin: A quantum leap?","volume":"18","author":"McIntyre","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.15585\/mmwr.mm6903a5","article-title":"Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2019","volume":"69","author":"Havers","year":"2020","journal-title":"MMWR-Morb. Mortal. Wkly. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pool, V., Mege, L., and Abou-Ali, A. (2020). Arthus Reaction as an Adverse Event Following Tdap Vaccination. Vaccines, 8.","DOI":"10.3390\/vaccines8030385"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eclinm.2019.06.010","article-title":"The effect of maternal immunisation during pregnancy on infant vaccine responses","volume":"13","author":"Zimmermann","year":"2019","journal-title":"eClinicalMedicine"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Phiriyasart, F., Chongsuvivatwong, V., and Kumwichar, P. (2026). Real-world effectiveness of maternal genetically inactivated acellular pertussis vaccination in protecting infants under three months of age: A case-control study using concurrent community-based and test-negative controls. Infection.","DOI":"10.1007\/s15010-026-02868-x"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Vygen-Bonnet, S., Hellenbrand, W., Garbe, E., von Kries, R., Bogdan, C., Heininger, U., R\u00f6bl-Mathieu, M., and Harder, T. (2020). Safety and effectiveness of acellular pertussis vaccination during pregnancy: A systematic review. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-4824-3"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/14787210.2025.2516556","article-title":"Challenges associated with pertussis detection, monitoring, and vaccination in adults","volume":"23","author":"Regan","year":"2025","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/ciz821","article-title":"Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study","volume":"71","author":"Liu","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2600443","DOI":"10.2807\/1560-7917.ES.2026.31.23.2600443","article-title":"Diphtheria outbreak, Northern Territory of Australia, 2025 to 2026","volume":"31","author":"Draper","year":"2026","journal-title":"Eurosurveillance"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"126251","DOI":"10.1016\/j.vaccine.2024.126251","article-title":"Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents","volume":"42","author":"Richmond","year":"2024","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101211","DOI":"10.1016\/j.lanmic.2025.101211","article-title":"Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: A randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis","volume":"6","author":"Gbesemete","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"ofae631.191","DOI":"10.1093\/ofid\/ofae631.191","article-title":"596. Immunogenicity and Safety of BPZE1, an Intranasal Live Attenuated Pertussis Vaccine, Evaluated with and Without Tdap in Healthy Children 6 to 17 Years Old: A Phase 2b, Randomized, Active-Controlled Study","volume":"12","author":"Faust","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8194","DOI":"10.1016\/j.vaccine.2020.10.070","article-title":"Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen\u00ae) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen\u00ae) vaccine for immunization of adolescents and adults in Thailand","volume":"38","author":"Fortuna","year":"2020","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e1087","DOI":"10.1093\/cid\/ciac432","article-title":"Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccination During Pregnancy: Impact on Infant Anti-Pertussis Antibody Concentrations by Maternal Pertussis Priming Series","volume":"76","author":"Havers","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2547732","DOI":"10.1080\/22221751.2025.2547732","article-title":"Evaluation of immune responses to Tdap booster during pregnancy in women who received whole cell or acellular pertussis vaccines during childhood","volume":"14","author":"Hall","year":"2025","journal-title":"Emerg. Microbes Infect."},{"key":"ref_64","unstructured":"Clinicaltrials.gov (2026, August 19). [NCT05193734]. Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-Detoxified Pertussis Toxin in Young Adults Previously Primed with Acellular Pertussis Vaccines (Pertagen2x), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05193734."},{"key":"ref_65","unstructured":"Clinicaltrials.gov (2026, August 19). [NCT06803524]. 10-Year Follow-Up After a Single Dose Acellular Pertussis Vaccination, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06803524."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:50:31Z","timestamp":1788241831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":65,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090736"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090736","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]}}}